Xencor (XNCR)

• Market cap: $1.14B
• 1 day: 2.56%
• 5 days: 8.39%
• 1 month: 6.3%
• 3 months: 105.12%
• 6 months: 98.76%
• Year to date: -32.66%
• 1 year: -30.92%
• 5 years: -60.65%
• 10 years: 15.42%
• Sector: Healthcare
• Industry: Biotechnology

About: Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

Employees: 250